Company Analysis
Sign in

BioMarin Pharmaceutical Inc. (BMRN)

Nasdaq: BMRN · Pharmaceutical Preparations · Novato, CA · filing with the SEC since 1999
Full chart Alerts Compare
Grade6.5
◀ Past 7.2● Present 6.6▶ Future 5.7
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart

Patents

US patents through Dec 31, 2025 · PatentsView, from the USPTO’s Open Data Portal · read Oct 27, 2026

135 patents granted to the 2 names below, as the owner printed on each patent when it was granted. A later sale, a lapse or an expiry is not read, so this is what was granted to BioMarin Pharmaceutical Inc.’s names, not what it holds today.

Patents granted
135
132 utility, 3 reissue, 1976 to Dec 31, 2025
Granted in 2025
4
Against 3 in 2024 and 5 in 2023
Applications published
204
7 of them in 2025
Names they are printed under
2
its own name
By yearGrantedApplications published
'11'12'13'14'15'16'17'18'19'20'21'22'23'24'25
Each pair is one calendar year. Applications are published about eighteen months after filing, so the newest years read low.
What they are aboutgrants since 2021
Pharmaceuticals20
Organic fine chemistry2
Biotechnology2
Analysis of biological materials1
The main technology area of each patent, in the World Intellectual Property Organization’s 35 fields.
Under which name2 counted
BIOMARIN PHARMACEUTICAL INC. its own name
US, as the owner printed on each patent. 1 more under the same name are not counted (printed in CA)
135 granted
99 published
BIOMARIN PHARMACEUTICAL INC. its own name
named as the applicant on its applications, in US
0 granted
105 published
Newest grantseach row opens the USPTO’s own copy
GrantedPatentTitleFieldOwner as printed
Mar 4, 202512,239,692Adeno-associated virus factor VIII vectorsPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Feb 25, 202512,233,106C-type natriuretic peptide variants to treat skeletal dysplasia in childrenPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Feb 4, 202512,214,015Use of c-type natriuretic peptide variants to treat osteoarthritisPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Jan 7, 202512,188,058Manufacture of active highly phosphorylated human lysosomal sulfatase enzymes and uses thereofPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Sep 3, 202412,076,372Use of C-type natriuretic peptide variants to treat skeletal dysplasiaPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Mar 5, 202411,918,633Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating adolescent subjectsPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Feb 27, 202411,911,446Use of C-type natriuretic peptide variants to treat skeletal dysplasiaPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Nov 21, 202311,821,008Liver targeting adeno-associated viral vectorsBiotechnologyBIOMARIN PHARMACEUTICAL INC.
Aug 29, 202311,739,345Methods of treating phenylketonuriaBiotechnologyBIOMARIN PHARMACEUTICAL INC.
Jul 4, 202311,690,898Adeno-associated virus Factor VIII vectors, associated viral particles and therapeutic formulations comprising the samePharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Newest applications publishedan application is a clue, never a plan
PublishedApplicationTitleFieldOwner as printed
Dec 25, 20252025/0388644TARGETED THERAPEUTIC LYSOSOMAL ENZYME FUSION PROTEINS AND USES THEREOFBiotechnologyBIOMARIN PHARMACEUTICAL INC.
Oct 30, 20252025/0332224Adeno-Associated Virus Factor VIII VectorsPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
May 29, 20252025/0170217C-TYPE NATRIURETIC PEPTIDE VARIANTS TO TREAT SKELETAL DYSPLASIA IN CHILDRENPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
May 22, 20252025/0161466CONJUGATES OF PHENYLALANINE AMMONIA-LYASE AND POEGMA AND METHODS FOR THEIR USEPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Apr 17, 20252025/0122530AAV CAPSID COMPOSITIONS AND METHODS FOR DELIVERYBiotechnologyBIOMARIN PHARMACEUTICAL INC.
Mar 13, 20252025/0084383LARGE SCALE ADENO-ASSOCIATED VIRUS PRODUCTION SYSTEMSBiotechnologyBIOMARIN PHARMACEUTICAL INC.
Jan 30, 20252025/0032576CNP TherapyAnalysis of biological materialsBIOMARIN PHARMACEUTICAL INC.
Dec 12, 20242024/0408240TREATMENT OF HEREDITARY ANGIOEDEMA WITH AAV GENE THERAPY VECTORS AND THERAPEUTIC FORMULATIONSPharmaceuticalsBIOMARIN PHARMACEUTICAL INC.
Nov 21, 20242024/0384242AAV CAPSID COMPOSITIONS AND METHODS FOR DELIVERYBiotechnologyBIOMARIN PHARMACEUTICAL INC.
Nov 14, 20242024/0376496AAV CAPSID COMPOSITIONS AND METHODS FOR DELIVERYBiotechnologyBIOMARIN PHARMACEUTICAL INC.
What it applied for, 2024 to 2025: Pharmaceuticals 11 · Biotechnology 10 · Analysis of biological materials 1.

A patent is counted where the owner printed on it when it was granted carries the company’s own name, a former name, the name of a subsidiary its annual report lists, or its own name with a patent-holding phrase (Technology Licensing, Intellectual Property and the like), once the legal form, case and punctuation are set aside, and prints a country that name counts in. PatentsView’s data are published under the Creative Commons Attribution 4.0 licence. Source: PatentsView's granted patents and pre-grant publications, disambiguated, from the USPTO's Open Data Portal, through Dec 31, 2025, read Oct 27, 2026.

SI Assistanton BMRN · research, not advice